AbCellera Biologics ABCL
NASDAQ ABCL
$12.50 +0.62 (+5.22%)
At close: Nov 9, 2026 · 4:00 PM EST

AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021)

Updated

AbCellera Biologics' Receivables - Other came in at $62.09 million for Q2 2021, down 67.8% from the prior quarter.

Analysis

AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021) Analysis & Trends

At the end of FY2020, AbCellera Biologics' Receivables - Other was $212.34 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 AbCellera Biologics 3.83 Bn 3.29 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 62.09 Mn
Mar 31, 2021 193.07 Mn
Dec 31, 2020 212.34 Mn
API Access

AbCellera Biologics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=ABCL&period=max&api_key=YOUR_API_KEY